Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
Showing 1799 results
February 2021
-
Media ReleaseNovartis data show multiple sclerosis patients and nurses prefer Kesimpta® (ofatumumab) Sensoready® autoinjector penMulticenter survey results show MS patients and nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta over other autoinjectors for their current treatment (84…
-
Featured NewsExpanding CAR-T manufacturing in Australia
Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with life-threatening blood cancers.
Novartis global commercial CAR-T manufacturing footprint now spans four continents, bringing these transformative therapies closer to patients and healthcare professionals around the world. -
Media ReleaseSandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibioticsSandoz to acquire three established brands sold in more than 100 marketsAcquisition, including leading global brand Zinnat®, confirms Sandoz commitment to antibiotics, following plans to expand its…
-
Media ReleaseNovartis receives FDA Breakthrough Therapy designations for investigational STAMP inhibitor asciminib (ABL001) in chronic myeloid leukemiaDesignation in patients with chronic myeloid leukemia (CML) resistant or intolerant to prior treatments based on positive data from pivotal Phase III ASCEMBL trial evaluating asciminib, an…
-
Featured NewsWorld Cancer Day 2021
We’re honoring World Cancer Day with a new series called “Let’s Talk About the C Word: From Cancer to Cures” to address challenging conversations on cancer.
January 2021
-
Key ReleaseNovartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosisKesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS1CHMP opinion is…
-
Media ReleaseNovartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccineFirst of multiple agreements being explored by Novartis to leverage manufacturing capacity and capabilities to address pandemic, supporting global supply of COVID-19 vaccine Initial agreement signed…
-
Media ReleaseNovartis renews WHO medicine donation pledge with aim of ending leprosyNovartis leprosy medicine donation program with WHO extended to 2025 Program has already treated over 7 million patients since 2000 New evidence from contact tracing and preventive treatment…
-
Featured NewsNovartis ranks second in 2021 Access to Medicine Index
Novartis maintained its position in the 2021 Access to Medicine Index, leading in its approach to product delivery, while performing strongly across all other areas of the Index.
-
Key ReleaseEn 2020, Novartis a enregistré une croissance de son chiffre d’affaires et de sa marge; il a continué de faire progresser sa prochaine vague de médicamentsChiffre d’affaires net des activités poursuivies1 en hausse de 3% (tcc2, +3% USD): Pharmaceuticals: cette unité opérationnelle a progressé de 5% (tcc), soutenue par Entresto (+44%…
-
Key ReleaseNovartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetriebenDer Nettoumsatz der fortzuführenden Geschäftsbereiche¹ stieg im Geschäftsjahr um 3% (kWk², +3% USD): Die Geschäftseinheit Pharmaceuticals wuchs um 5% (kWk), wozu vor allem Entresto (+44%…
-
Key ReleaseNovartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.Full year net sales from continuing operations¹ up 3% (cc², +3% USD): Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13% cc…